Exploring the Therapeutic Landscape: The Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients With Cirrhosis

被引：0
|
作者：
Gudushauri, Nino [1 ]
Lemonjava, Irakli [1 ]
Azmaiparashvili, Zurab [1 ]
Mohan, Nandakumar [2 ]
Tskhakaia, Irakli [1 ]
Byfield, Karecia [3 ]
Anebo, Tinsae [3 ]
机构：
[1] Jefferson Einstein Hosp, Philadelphia, PA USA
[2] Einstein Healthcare Network, Philadelphia, PA USA
[3] Albert Einstein Med Ctr, Philadelphia, PA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001036756.32599.c9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1847
引用
收藏
页码：S1330 / S1330
页数：1
相关论文
共 50 条
  • [31] Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Mariana Tinoco, M.
    Cardoso, F.
    Dias, G.
    Pereira, T.
    Faria, B.
    Almeida, F.
    Leite, S.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 112 - 112
  • [32] SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases
    Di Costanzo, Assunta
    Esposito, Giovanni
    Indolfi, Ciro
    Spaccarotella, Carmen Anna Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (10)
  • [33] Clinical Outcomes in Patients with Type 2 Diabetes Newly Initiating SGLT2 or DPP4 Inhibitors
    Adimadhyam, Sruthi
    Isaman, Danielle
    Weckstein, Andrew
    Payne, Emma
    Yu, Edward
    Louder, Anthony
    Reynolds, Shannon L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 36 - 37
  • [34] Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials
    George Bazoukis
    Stamatis S.Papadatos
    Costas Thomopoulos
    Gary Tse
    Stefanos Cheilidis
    Konstantinos Tsioufis
    Dimitrios Farmakis
    Journal of Geriatric Cardiology, 2021, 18 (10) : 783 - 795
  • [35] Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials
    Bazoukis, George
    Papadatos, Stamatis S.
    Thomopoulos, Costas
    Tse, Gary
    Cheilidis, Stefanos
    Tsioufis, Konstantinos
    Farmakis, Dimitrios
    JOURNAL OF GERIATRIC CARDIOLOGY, 2021, 18 (10) : 783 - 795
  • [36] Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations
    Mohite, Prasanna
    Lokwani, Deepak K.
    Sakle, Nikhil S.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (08) : 6107 - 6119
  • [37] SGLT2 Inhibitors and Safety in Older Patients
    Pollack, Rena
    Cahn, Avivit
    HEART FAILURE CLINICS, 2022, 18 (04) : 635 - 643
  • [38] Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin
    Saffo, Saad
    Kaplan, David E.
    Mahmud, Nadim
    Serper, Marina
    John, Binu V.
    Ross, Joseph S.
    Taddei, Tamar
    DIABETES OBESITY & METABOLISM, 2021, 23 (10): : 2402 - 2408
  • [39] SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives
    Tan, Jiang-Shan
    Wei, Yixiao
    Chong, Lingtao
    Yang, Yanmin
    Hu, Song
    Wang, Yimeng
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2024, 61 (08) : 709 - 725
  • [40] Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
    Palmiero, Giuseppe
    Cesaro, Arturo
    Vetrano, Erica
    Pafundi, Pia Clara
    Galiero, Raffaele
    Caturano, Alfredo
    Moscarella, Elisabetta
    Gragnano, Felice
    Salvatore, Teresa
    Rinaldi, Luca
    Calabro, Paolo
    Sasso, Ferdinando Carlo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
12345